- Home
- JRS vs ANGO Comparison
JRS vs ANGO Comparison
Compare JRS & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- ANGO
- Stock Information
- Founded
- JRS 2001
- ANGO 1988
- Country
- JRS United States
- ANGO United States
- Employees
- JRS N/A
- ANGO N/A
- Industry
- JRS Finance/Investors Services
- ANGO Medical/Dental Instruments
- Sector
- JRS Finance
- ANGO Health Care
- Exchange
- JRS Nasdaq
- ANGO Nasdaq
- Market Cap
- JRS 267.5M
- ANGO 271.1M
- IPO Year
- JRS N/A
- ANGO 2004
- Fundamental
- Price
- JRS $9.05
- ANGO $6.81
- Analyst Decision
- JRS
- ANGO Strong Buy
- Analyst Count
- JRS 0
- ANGO 4
- Target Price
- JRS N/A
- ANGO $12.00
- AVG Volume (30 Days)
- JRS 86.6K
- ANGO 512.7K
- Earning Date
- JRS 01-01-0001
- ANGO 01-03-2025
- Dividend Yield
- JRS 8.87%
- ANGO N/A
- EPS Growth
- JRS N/A
- ANGO N/A
- EPS
- JRS N/A
- ANGO N/A
- Revenue
- JRS N/A
- ANGO $292,726,000.00
- Revenue This Year
- JRS N/A
- ANGO N/A
- Revenue Next Year
- JRS N/A
- ANGO $7.69
- P/E Ratio
- JRS N/A
- ANGO N/A
- Revenue Growth
- JRS N/A
- ANGO N/A
- 52 Week Low
- JRS $5.95
- ANGO $5.26
- 52 Week High
- JRS $8.00
- ANGO $8.25
- Technical
- Relative Strength Index (RSI)
- JRS 50.21
- ANGO 47.01
- Support Level
- JRS $8.67
- ANGO $7.04
- Resistance Level
- JRS $9.45
- ANGO $7.51
- Average True Range (ATR)
- JRS 0.17
- ANGO 0.29
- MACD
- JRS 0.02
- ANGO -0.00
- Stochastic Oscillator
- JRS 48.29
- ANGO 25.53
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies. At least 75% of the Fund's managed assets will be in securities rated investment grade.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.